{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:20:24Z","timestamp":1788848424470,"version":"build-2803163510"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR002537"],"award-info":[{"award-number":["UL1 TR002537"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006939","name":"Emory","doi-asserted-by":"publisher","award":["HHSN272201300015I"],"award-info":[{"award-number":["HHSN272201300015I"]}],"id":[{"id":"10.13039\/100006939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007856","name":"Baylor College of Medicine","doi-asserted-by":"publisher","award":["HHSN272201300020I"],"award-info":[{"award-number":["HHSN272201300020I"]}],"id":[{"id":"10.13039\/100007856","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Iowa and National Center for Advancing Translational Sciences"},{"DOI":"10.13039\/100008893","name":"University of Iowa","doi-asserted-by":"publisher","award":["HHSN27220130021I"],"award-info":[{"award-number":["HHSN27220130021I"]}],"id":[{"id":"10.13039\/100008893","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008137","name":"Saint Louis University","doi-asserted-by":"publisher","award":["HHSN2722013000017I"],"award-info":[{"award-number":["HHSN2722013000017I"]}],"id":[{"id":"10.13039\/501100008137","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006510","name":"Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008065","name":"Georgia Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007623","name":"Emory University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007623","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012423","name":"Children\u2019s Healthcare of Atlanta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016027","name":"NYU Grossman School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"US Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021704","name":"Administration for Strategic Preparedness and Response","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"BARDA","doi-asserted-by":"publisher","award":["HHSO100201600004I"],"award-info":[{"award-number":["HHSO100201600004I"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"BARDA","doi-asserted-by":"publisher","award":["HHSO100201600006I"],"award-info":[{"award-number":["HHSO100201600006I"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>A surge of human influenza A(H7N9) cases began in 2016 in China from an antigenically distinct lineage. Data are needed about the safety and immunogenicity of 2013 and 2017 A(H7N9) inactivated influenza vaccines (IIVs) and the effects of AS03 adjuvant, prime-boost interval, and priming effects of 2013 and 2017 A(H7N9) IIVs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Healthy adults (n = 180), ages 19\u201350 years, were enrolled into this partially blinded, randomized, multicenter phase 2 clinical trial. Participants were randomly assigned to 1 of 6 vaccination groups evaluating homologous versus heterologous prime-boost strategies with 2 different boost intervals (21 vs 120 days) and 2 dosages (3.75 or 15\u2005\u03bcg of hemagglutinin) administered with or without AS03 adjuvant. Reactogenicity, safety, and immunogenicity measured by hemagglutination inhibition and neutralizing antibody titers were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two doses of A(H7N9) IIV were well tolerated, and no safety issues were identified. Although most participants had injection site and systemic reactogenicity, these symptoms were mostly mild to moderate in severity; injection site reactogenicity was greater in vaccination groups receiving adjuvant. Immune responses were greater after an adjuvanted second dose, and with a longer interval between prime and boost. The highest hemagglutination inhibition geometric mean titer (95% confidence interval) observed against the 2017 A(H7N9) strain was 133.4 (83.6\u2013212.6) among participants who received homologous, adjuvanted 3.75\u2005\u00b5g + AS03\/2017 doses with delayed boost interval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Administering AS03 adjuvant with the second H7N9 IIV dose and extending the boost interval to 4 months resulted in higher peak antibody responses. These observations can broadly inform strategic approaches for pandemic preparedness. Clinical Trials Registration. NCT03589807.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciae173","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T15:48:39Z","timestamp":1711468119000},"page":"1757-1768","source":"Crossref","is-referenced-by-count":13,"title":["A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8439-0592","authenticated-orcid":false,"given":"Christina A","family":"Rostad","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine , Atlanta, Georgia , USA"},{"name":"Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L","family":"Atmar","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel B","family":"Walter","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Duke Human Vaccine Institute, Duke University , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Frey","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, Saint Louis University , St. Louis, Missouri , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery L","family":"Meier","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Iowa , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C","family":"Sherman","sequence":"additional","affiliation":[{"name":"Hope Clinic, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilin","family":"Lai","sequence":"additional","affiliation":[{"name":"Hope Clinic, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Tsong","sequence":"additional","affiliation":[{"name":"Emmes, Inc. , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol M","family":"Kao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine , Atlanta, Georgia , USA"},{"name":"Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Raabe","sequence":"additional","affiliation":[{"name":"Hope Clinic, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia , USA"},{"name":"New York University Langone Vaccine Center, NYU Grossman School of Medicine , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana M","family":"El Sahly","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A","family":"Keitel","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A","family":"Whitaker","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Duke Human Vaccine Institute, Duke University , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E","family":"Schmader","sequence":"additional","affiliation":[{"name":"Department of Medicine-Geriatrics, Duke University and GRECC, Durham VA Health Care System , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta K","family":"Swamy","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology and Duke Human Vaccine Institute, Duke University , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getahun","family":"Abate","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, Saint Louis University , St. Louis, Missouri , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Winokur","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Iowa , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Buchanan","sequence":"additional","affiliation":[{"name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Cross","sequence":"additional","affiliation":[{"name":"Emmes, Inc. , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Wegel","sequence":"additional","affiliation":[{"name":"Emmes, Inc. , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Xu","sequence":"additional","affiliation":[{"name":"Hope Clinic, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inci","family":"Yildirim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine , Atlanta, Georgia , USA"},{"name":"Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kamidani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine , Atlanta, Georgia , USA"},{"name":"Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Rouphael","sequence":"additional","affiliation":[{"name":"Hope Clinic, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C","family":"Roberts","sequence":"additional","affiliation":[{"name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J","family":"Mulligan","sequence":"additional","affiliation":[{"name":"Hope Clinic, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia , USA"},{"name":"New York University Langone Vaccine Center, NYU Grossman School of Medicine , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine , Atlanta, Georgia , USA"},{"name":"Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta , Atlanta, Georgia , USA"},{"name":"Hope Clinic, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"2024061323554926200_ciae173-B1","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMp2213814","article-title":"It ain\u2019t over till it\u2019s over \u2026 but it\u2019s never over\u2014emerging and reemerging infectious diseases","volume":"387","author":"Fauci","year":"2022","journal-title":"N Engl J Med"},{"key":"2024061323554926200_ciae173-B2","doi-asserted-by":"crossref","first-page":"ciac982","DOI":"10.1093\/cid\/ciac982","article-title":"Safety and immunogenicity of influenza A\/H5N8 virus vaccine in healthy adults: durability and cross-reactivity of antibody responses","author":"Neuzil","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024061323554926200_ciae173-B3","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3201\/eid1805.111922","article-title":"Human infections with novel reassortant influenza A(H3N2)v viruses, United States, 2011","volume":"18","author":"Lindstrom","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"2024061323554926200_ciae173-B4","article-title":"First human case of avian influenza A (H5N6) in Yunnan province, China","volume":"3","author":"He","year":"2015","journal-title":"SAGE Open Med Case Rep"},{"key":"2024061323554926200_ciae173-B5","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0140-6736(99)03311-5","article-title":"Human infection with influenza H9N2","volume":"354","author":"Peiris","year":"1999","journal-title":"Lancet"},{"key":"2024061323554926200_ciae173-B6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1056\/NEJMoa0904252","article-title":"Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico","volume":"361","author":"Perez-Padilla","year":"2009","journal-title":"N Engl J Med"},{"key":"2024061323554926200_ciae173-B7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1126\/science.279.5349.393","article-title":"Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness","volume":"279","author":"Subbarao","year":"1998","journal-title":"Science"},{"key":"2024061323554926200_ciae173-B8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3201\/eid2301.161122","article-title":"Whole-genome characterization of a novel human influenza A(H1N2) virus variant, Brazil","volume":"23","author":"Resende","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2024061323554926200_ciae173-B9","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","article-title":"Human infection with a novel avian-origin influenza A (H7N9) virus","volume":"368","author":"Gao","year":"2013","journal-title":"N Engl J Med"},{"key":"2024061323554926200_ciae173-B10","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.2014.12854","article-title":"Serological responses to an avian influenza A\/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Mulligan","year":"2014","journal-title":"JAMA"},{"key":"2024061323554926200_ciae173-B11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA"},{"key":"2024061323554926200_ciae173-B12","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.vaccine.2020.11.051","article-title":"Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older","volume":"39","author":"Winokur","year":"2021","journal-title":"Vaccine"},{"key":"2024061323554926200_ciae173-B13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/infdis\/jiy408","article-title":"Antigenic drift of influenza A(H7N9) virus hemagglutinin","volume":"219","author":"Ning","year":"2019","journal-title":"J Infect Dis"},{"key":"2024061323554926200_ciae173-B14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jinf.2017.04.002","article-title":"Evolving HA and PB2 genes of influenza A (H7N9) viruses in the fifth wave\u2014increasing threat to both birds and humans?","volume":"75","author":"Li","year":"2017","journal-title":"J Infect"},{"key":"2024061323554926200_ciae173-B15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.chom.2017.09.008","article-title":"A highly pathogenic avian H7N9 influenza virus isolated from a human is lethal in some ferrets infected via respiratory droplets","volume":"22","author":"Imai","year":"2017","journal-title":"Cell Host Microbe"},{"key":"2024061323554926200_ciae173-B16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"key":"2024061323554926200_ciae173-B17","doi-asserted-by":"crossref","first-page":"e49704","DOI":"10.1371\/journal.pone.0049704","article-title":"A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine","volume":"7","author":"Couch","year":"2012","journal-title":"PLoS One"},{"key":"2024061323554926200_ciae173-B18","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"key":"2024061323554926200_ciae173-B19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/erv.09.5","article-title":"Emulsion-based adjuvants for influenza vaccines","volume":"8","author":"Vogel","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"2024061323554926200_ciae173-B20","doi-asserted-by":"crossref","first-page":"ofu091","DOI":"10.1093\/ofid\/ofu091","article-title":"Safety, reactogenicity, and immunogenicity of inactivated monovalent influenza A(H5N1) virus vaccine administered with or without AS03 adjuvant","volume":"1","author":"Chen","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"2024061323554926200_ciae173-B21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/infdis\/jir328","article-title":"Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults","volume":"204","author":"Lasko","year":"2011","journal-title":"J Infect Dis"},{"key":"2024061323554926200_ciae173-B22","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.vaccine.2013.04.050","article-title":"Safety and immunogenicity of IMVAMUNE\u00ae smallpox vaccine using different strategies for a post event scenario","volume":"31","author":"Frey","year":"2013","journal-title":"Vaccine"},{"key":"2024061323554926200_ciae173-B23","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.vaccine.2017.02.032","article-title":"Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: a randomized clinical non-inferiority trial","volume":"35","author":"Jackson","year":"2017","journal-title":"Vaccine"},{"key":"2024061323554926200_ciae173-B24","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1016\/j.vaccine.2014.08.076","article-title":"Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults","volume":"32","author":"Bernstein","year":"2014","journal-title":"Vaccine"},{"key":"2024061323554926200_ciae173-B25","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1038\/s41467-021-27410-5","article-title":"Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England","volume":"12","author":"Amirthalingam","year":"2021","journal-title":"Nat Commun"},{"key":"2024061323554926200_ciae173-B26","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiq093","article-title":"Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant","volume":"203","author":"Belshe","year":"2011","journal-title":"J Infect Dis"},{"key":"2024061323554926200_ciae173-B27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1086\/590916","article-title":"Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A\/Vietnam\/1203\/2004 (H5N1) vaccine after priming with an antigenic variant","volume":"198","author":"Goji","year":"2008","journal-title":"J Infect Dis"},{"key":"2024061323554926200_ciae173-B28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1471-2334-14-142","article-title":"Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults","volume":"14","author":"Gillard","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2024061323554926200_ciae173-B29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-022-04527-1","article-title":"Germinal centre-driven maturation of B cell response to mRNA vaccination","volume":"604","author":"Kim","year":"2022","journal-title":"Nature"},{"key":"2024061323554926200_ciae173-B30","doi-asserted-by":"crossref","first-page":"ciac983","DOI":"10.1093\/cid\/ciac983","article-title":"Safety and immunogenicity of a monovalent inactivated influenza A\/H5N8 virus vaccine given with and without AS03 or MF59 adjuvants in healthy adults","author":"Winokur","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024061323554926200_ciae173-B31","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMc2113891","article-title":"Receipt of mRNA Covid-19 vaccines and risk of spontaneous abortion","volume":"385","author":"Zauche","year":"2021","journal-title":"N Engl J Med"},{"key":"2024061323554926200_ciae173-B32","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1093\/infdis\/jiw310","article-title":"Priming vaccination with influenza virus H5 hemagglutinin antigen significantly increases the duration of T cell responses induced by a heterologous H5 booster vaccination","volume":"214","author":"Hoft","year":"2016","journal-title":"J Infect Dis"},{"key":"2024061323554926200_ciae173-B33","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1016\/j.vaccine.2022.03.055","article-title":"Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: a randomized clinical trial","volume":"40","author":"Ortiz","year":"2022","journal-title":"Vaccine"},{"key":"2024061323554926200_ciae173-B34","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"2024061323554926200_ciae173-B35","doi-asserted-by":"crossref","first-page":"e3001211","DOI":"10.1371\/journal.pbio.3001211","article-title":"Evaluation of COVID-19 vaccination strategies with a delayed second dose","volume":"19","author":"Moghadas","year":"2021","journal-title":"PLoS Biol"},{"key":"2024061323554926200_ciae173-B36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/infdis\/jiad276","article-title":"Safety and immunogenicity of a delayed heterologous avian influenza A(H7N9) vaccine boost following different priming regimens: a randomized clinical trial","volume":"229","author":"El Sahly","year":"2023","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae173\/57349838\/ciae173.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/6\/1757\/58212081\/ciae173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/6\/1757\/58212081\/ciae173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T09:43:46Z","timestamp":1718358226000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/6\/1757\/7636247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3,27]]},"published-print":{"date-parts":[[2024,6,14]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae173","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,15]]},"published":{"date-parts":[[2024,3,27]]}}}